Compare J M Smucker Co (SJM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs Summit Therapeutics Inc — how do they compare? J M Smucker Co trades at $123.61 (market cap $13.32B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: J M Smucker Co and Summit Therapeutics Inc are close in size by market cap, and J M Smucker Co pays a 3.59% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SJM | SMMT | |
|---|---|---|
Market Cap | $13.32B | $13.79B |
Sector | Consumer Staples | Health |
52-Week High | $132.34 | $26.38 |
52-Week Low | $89.53 | $12.43 |
Enterprise Value | $20.17B | $13.11B |
Dividend Yield | 3.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $124.66, down 1.13% on the day, with a bullish technical signal per moving averages despite oscillators showing bearish momentum. The company reported strong Q1 2027 earnings, beating estimates with EPS of $3.24, and raised full-year guidance. Valuation metrics include a P/E of 58.25 and P/S of 1.45, while recent news highlights CEO and CFO stock sales and positive analyst sentiment.
Outlook is positive with a consensus price target of $144.78, implying 16% upside, supported by earnings momentum and dividend yield. Risks include high debt levels, with debt-to-asset ratio at 43.71% in 2025, and volatile net income margins, which turned negative in 2025. Investors should weigh strong recent performance against financial leverage and insider selling activity.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
